GlassScriptPhysician profile
Olivia Cyr
NPI 1508699497
$3,102.30
in general payments reported to CMS, 2019-2025
19 companies · $2,634 in 2025
The $2,634 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $468 · 2025: $2,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,102.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,087.20 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $465.46 | 2024-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $269.55 | 2024-2025 | Wegovy, Ozempic |
| Axsome Therapeutics, INC. | $229.50 | 2024-2025 | Auvelity |
| Lilly USA, LLC | $163.06 | 2025 | Mounjaro, Zepbound, Kisunla |
| Astellas Pharma US INC | $144.90 | 2025 | Veozah |
| Pfizer INC. | $138.45 | 2025 | |
| Amgen INC. | $122.74 | 2024-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.10 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $83.78 | 2024-2025 | Spravato |
| Vertex Pharmaceuticals Incorporated | $49.62 | 2024-2025 | |
| Abbott Laboratories | $48.57 | 2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $42.56 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $38.46 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $38.38 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $33.73 | 2025 | Jornay Pm |
| Actelion Pharmaceuticals US, INC. | $19.68 | 2025 | Opsumit, Uptravi |
| Antares Pharma, INC. | $14.67 | 2025 | Xyosted |
| Currax Pharmaceuticals LLC | $13.89 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Cyr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.